REKOVELLE® PEN S.C. Injection 12μg/36μg/72μg for Controlled Ovarian Stimulation in Assisted Reproductive Technologies - General Drug Use-results Survey
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
Eligibility
Participation Requirements
Sex: Female
Healthy Volunteers: f
View:
• Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey.
Locations
Other Locations
Japan
Ferring Investigational Site
RECRUITING
Omitama
Contact Information
Primary
Global Clinical Compliance
DK0-Disclosure@ferring.com
+1 833-548-1402 (US/Canada)
Backup
Global Clinical Compliance
DK0-Disclosure@ferring.com
+1 862-286-5200 (outside US)
Time Frame
Start Date: 2022-09-16
Estimated Completion Date: 2029-06-22
Participants
Target number of participants: 500
Related Therapeutic Areas
Sponsors
Leads: Ferring Pharmaceuticals